Andelyn Biosciences Inc., a and patient-focused cell and gene therapy Contract Development and Manufacturing Organisation (CDMO), has been selected to manufacture adeno-associated vector (AAV) therapies in its suspension platform for several programmes under the Foundation for the National Institutes of Health (FNIH) Accelerating Medicines Partnership® (AMP®) Bespoke Gene Therapy Consortium (BGTC).
BGTC has chosen to focus on eight rare disease programmes, with Andelyn selected to optimise and scale the AAV therapy processes for the treatments of CNGB1 Retinitis Pigmentosa 45 and NPHP5 retinal degeneration.
Managed by the FNIH, AMP BGTC is a public-private partnership between the National Institutes of Health (NIH), the US Food and Drug Administration (FDA), biopharmaceutical and life science companies and nonprofit and other organisations with a mission to speed the development and delivery of AAV gene therapies that could treat the millions of people affected by rare diseases.
Matt Niloff, Chief Commercial Officer of Andelyn, commented, “As a long-standing pioneer in AAV gene therapies with a focus on patients, we have great synergies with the BGTC.”
“Andelyn is privileged to work with the FNIH/BGTC on its first AMP, which was established specifically to help overcome the major obstacles related to developing gene therapies for rare diseases.”
